Q1 2021

Filed Apr 27, 2021 · 10-Q · 27 days after period end · 0001091818-21-000055

Q1 2021 · 10-Q

Revenue—

Net Income

-$145.08K

N/M vs Q1 2020

EPS Diluted

$0.00

N/M vs Q1 2020

Operating Cash Flow-$32,346N/M

Same quarter

Metric	Q1 2021	Q1 2020	Q1 2019	Q1 2018
Revenue	—	—	$5.85K	—
Net Income	-$145.08K	-$158.04M	-$12.85K	-$23.97K
EPS Diluted	$0.00	-$10.35	$0.00	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bioforce Nanosciences Holdings, Inc. · CIK 1310488 · Engraved from SEC EDGAR